Senseonics Q1 revenue $2.5M; FDA approves Eversense E3 6-month CGM

Senseonics Holdings, Inc.

2022-Q1 EPS reported -$0.03 revenue$2,481,000

Q1 2022 total revenue $2.5M vs $2.8M YoY; U.S. revenue $0.8M up from $0.3M.
Net income $86.7M ($0.19 EPS) vs net loss $249.5M (-$0.68 EPS) due to derivatives fair value adjustments.
FDA approved Eversense E3 CGM with 6-month sensor wear; U.S. commercial launch underway with Ascensia.
FY 2022 global revenue guidance reiterated at $14M-$18M.
Cash & investments $166.9M, debt $104.7M as of March 31, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.